September 2026 Research Update

This month, the research picture on preventing relapse in IgG4-related disease is still early. Small observational studies and single-patient reports suggest several immune-suppressing medicines can help keep disease under control after a flare, but results vary by person and by which organs are involved. A larger blinded trial is underway to test whether adding a long-term medicine can reduce relapses in people whose blood IgG4 rises again without clear symptoms. [1] [2] [3] [4] [5] [6] [7]

A multicentre randomized, double-blind, placebo-controlled trial in China has completed recruitment and is now being analyzed. It is testing whether adding low-dose mycophenolate mofetil for 52 weeks reduces relapse in adults on maintenance treatment who have a re-rise in blood IgG4 (at least a 30% increase and above the lab upper limit) but no clinical relapse at the time of enrollment. [1]

In a 7-person observational report of recurrent IgG4-related disease, 6 people had a complete response over 6 months after starting tofacitinib, with lower disease activity scores and lower blood IgG4. One person relapsed, and the main reported side effect was a mild case of shingles. [2]

In a 58-person retrospective cohort from a multiethnic US health system, organ involvement patterns were reported as broadly similar across racial groups, but rituximab use differed by racial group (no Black patients received it), and the study could not tell whether this reflected access barriers or differences in disease. Among people who received rituximab, decreases over time in the IgG4-to-total IgG ratio tracked with better treatment response, while orbital or tear gland involvement was linked with a higher chance of not responding to rituximab. [3]

Several case reports described longer-term control after treatment, but each reflects a single patient and may not apply to others. One man with IgG4-related kidney inflammation (along with other kidney diseases) improved after steroids and then rituximab, with stable kidney function and normalized blood IgG4 over 32 months. [4]

Other one-patient reports described sustained remission after treatment in specific organ settings: intestinal IgG4-related disease with small bowel ulcers and mesenteric inflammation remained in remission for 1 year after surgery and immune-suppressing medicines, although nerve side effects led to stopping thalidomide. Another patient had autoimmune pancreatitis that improved on its own, followed years later by bile duct involvement that improved quickly with steroids; during tapering, a separate medication was suspected to cause temporary liver injury. [5] [6]

A further case report described IgG4-related inflammation around the aorta and in the retroperitoneum where blood IgG4 was normal, yet symptoms and imaging improved after steroids plus azathioprine, and steroids were later stopped. This highlights that relapse monitoring cannot rely only on blood IgG4 values in every person. [7]

For patients and caregivers, these papers mainly add background context rather than changing care today: most evidence here is from small, non-randomized studies or individual cases, which cannot show which option is best for most people. The ongoing blinded trial is designed to answer a practical question about relapse prevention when blood IgG4 rises again without symptoms, but results are not yet available. Across studies, researchers are also trying to identify who is more or less likely to respond to treatments like rituximab (for example, based on certain organ involvement or changes in blood ratios), but these are still exploratory and need confirmation.

Across these papers, IgG4-related disease repeatedly appeared cancer-like on scans or as a mass, especially when it involved lymph nodes, lungs, the eye socket, or the testis. The overall message was that a combination of blood tests, imaging patterns, and tissue sampling is often used to sort IgG4-related disease from lymphoma or other cancers, and that no single clue is definitive in every situation. Most evidence here is from small, retrospective studies or single-patient reports, so results need confirmation in larger groups. [8] [9] [10] [11] [12]

In one retrospective study of adults with enlarged lymph nodes, a three-part tool using lymphocyte count, total blood protein, and prothrombin time helped separate IgG4-related disease from diffuse large B-cell lymphoma in that center's patients. The model had strong accuracy in the same dataset (area under the curve 0.91), but the authors noted it still needs external testing in other hospitals and larger groups. In plain terms, it suggests that routine lab patterns might raise or lower suspicion for lymphoma versus IgG4-related disease, but it is not yet a broadly proven test. [8]

For lung-only disease, an eight-patient case series showed that IgG4-related disease could look like cancer when there was a single lung lesion, or like infection when there were multiple lesions. In this small group, blood tumor markers and microbiology tests were negative, and all patients had high blood IgG4 levels; tissue biopsy supported the diagnosis. This reinforces that lung imaging alone may not clearly separate IgG4-related disease from malignancy. [9]

In orbital disease (around the eye), a retrospective MRI study found that some scan features and diffusion measurements differed between inflammatory disease and lymphoma, with higher diffusion values in granulomatosis with polyangiitis and IgG4-related orbital disease than in lymphoma. However, diffusion values overlapped between granulomatosis with polyangiitis and IgG4-related orbital disease, meaning MRI could help with some distinctions but not all. The same study noted that tissue necrosis on MRI occurred only in granulomatosis with polyangiitis in this dataset (20%), and certain outside-the-orbit findings were more common there, which may help narrow possibilities when doctors are deciding among look-alike conditions. [10]

Two single-patient reports illustrate how IgG4-related disease can be mistaken for cancer or other causes but remain difficult to prove without tissue. One man had a painless testicular mass treated as suspected cancer, and the diagnosis of isolated testicular IgG4-related disease was made only after surgery using tissue staining for IgG4-positive immune cells; he had no recurrence at 12 months. Another man had chest pain and a heart scan showing a soft-tissue "cuff" around coronary arteries suggestive of IgG4-related coronary inflammation, but because no tissue sample was obtained, the diagnosis remained clinical and the role of that process in the artery narrowing was uncertain. [11] [12]

For patients and caregivers, these reports mainly provide background on why IgG4-related disease can lead to a cancer workup: it may form lumps, enlarge lymph nodes, or create scan findings that resemble lymphoma or solid tumors. The most immediately relevant takeaways are that (1) routine blood tests and (2) certain imaging patterns may sometimes support one explanation over another, but (3) uncertainty often remains until tissue is examined, and some organ-specific situations may never have definitive proof if biopsy is not done. Because much of the evidence here is small or single-center, it is still unclear how well these tools perform across different hospitals, populations, and organ sites.

Across two case reports, IgG4-related disease affected the protective layers around the brain or spinal cord (meninges), causing major nervous system symptoms that developed over time. In both patients, tissue testing showed many IgG4-positive immune cells, and steroid treatment was followed by clear symptom improvement and improved MRI appearance. Because these are single-patient reports, it is still uncertain how often these patterns occur and which tests are most reliable in broader groups. [13] [14]

One 78-year-old woman developed complete paraplegia with bladder and bowel problems from thickened dura compressing the spinal cord (hypertrophic pachymeningitis). Her blood IgG4 level was normal, but IgG4 in spinal fluid was markedly elevated, and biopsy supported an IgG4-related process; after surgical decompression and high-dose steroids, her nerve function and MRI dural thickening improved, although she later relapsed and received additional immune-suppressing treatment. [13]

One 74-year-old man developed slowly progressive unsteady walking (ataxia) and reduced alertness due to inflammation of the pia mater (leptomeningitis). Brain MRI showed abnormal enhancement along the brain surface coverings, spinal fluid showed inflammation, and biopsy found a high proportion of IgG4-positive cells; intravenous steroids followed by oral steroids led to rapid improvement in consciousness and reduced MRI enhancement. [14]

For patients and caregivers, these reports add examples of how IgG4-related disease can involve the nervous system by inflaming the membranes around the brain or spinal cord, with symptoms ranging from balance problems and confusion to severe weakness or paralysis. The main value right now is awareness and background knowledge: the papers suggest that imaging, spinal fluid testing, and sometimes biopsy may be used to sort out the cause, and that blood IgG4 can be normal even when the nervous system is involved. What remains uncertain is how well spinal fluid IgG4 testing works in general, and how often people relapse after initial improvement, because each report describes only one person.

Across this paper, the main message is that IgG4-related disease can involve multiple heart and blood vessel tissues at the same time and may not cause clear symptoms before a serious event. The evidence here comes from a single case report, so it cannot show how often this happens or who is at highest risk. [15]

In a forensic autopsy of one person who died suddenly, IgG4-related disease was found in the ascending aorta, the sac around the heart (pericardium), the coronary arteries, the heart muscle, and the heart's built-in nerve network. Tissue review showed heavy immune-cell inflammation with a scarring pattern typical of IgG4-related disease, plus a high number of IgG4-positive plasma cells and a high IgG4-to-IgG ratio. [15]

The authors suggested a possible link between scarring in the heart muscle and inflammation around cardiac nerves and a risk of abnormal heart rhythms, as one potential explanation for sudden death. This mechanism is a proposal based on what was seen under the microscope in one case, and it has not been proven to apply to other people with IgG4-related disease. [15]

For patients and caregivers, this report mainly serves as background information that IgG4-related disease can, in rare situations, affect the heart and major blood vessels without being recognized beforehand. Because it describes one individual, it cannot estimate risk or define typical warning signs, and it does not show which tests would reliably detect this problem early. Larger studies would be needed to understand how common silent heart and vessel involvement is and which patterns of IgG4-related disease are most likely to include it. [15]

This months papers linked IgG4-related disease to two practical issues outside the more commonly discussed organs: skin lumps (nodules) and changes in blood counts. Together, they suggest that skin and spleen involvement can be part of the same condition, and that low platelets may be more likely when the spleen is enlarged, though not every patient is affected. [16] [17]

In a retrospective study of 56 people with IgG4-related disease, low platelets were common, occurring in 24/56 patients, while low white blood cells occurred in 6/56. Low platelets were more frequent in older patients and in those with an enlarged spleen, and spleen enlargement was linked to lower platelet and lymphocyte counts. [17]

In that same group, most people who received glucocorticoids (steroid medicines) had improvement in blood counts within 12 weeks. Because this was a chart review, it cannot prove exactly why counts improved or how often this happens in other clinics. [17]

A separate single-patient report described a 93-year-old woman with subcutaneous nodules on the knees caused by cutaneous (skin) IgG4-related disease. The tissue showed scarring (fibrosis), many IgG4-positive immune cells, and an unusual feature: granulomatous inflammation affecting blood vessels (vasculitis) with blood vessel destruction; her skin lesions improved after systemic corticosteroids. Because this is one case, it mainly shows what can happen rather than how common it is. [16]

For patients and caregivers, these studies add context that IgG4-related disease can involve the skin (as nodules) and may also relate to low blood counts, particularly low platelets, sometimes alongside an enlarged spleen. The blood count study is more informative about frequency but comes from a single center and a modest number of patients, while the skin paper is a rare case that highlights an unusual pattern of blood vessel inflammation in the skin. What remains uncertain is how often these skin patterns occur and which patients are most likely to develop significant blood count changes across different settings. [16] [17]

Across these studies, IgG4-related disease biology looked less like a single immune pathway and more like an interaction between immune cells and the local tissue environment, with signals pointing to long-running inflammation, immune cell exhaustion, and pathways linked to scarring. The evidence is exploratory and based on tissue gene activity patterns rather than direct proof of cause and effect. [18] [19]

In IgG4-related inflammation of the tear and salivary glands, aging was tied to higher activity of gene programs linked to chronic inflammation and immune exhaustion, along with stronger fibroblast and scarring (fibrosis) signatures. Older patients were also more likely to fall into more advanced "pseudo-stages" of fibrosis based on gene patterns, while germinal center B-cell programs showed minimal links to age. [18]

A separate case series suggested that M2-type macrophages (an immune cell state often linked to wound-healing and scarring signals) were active in affected tissues, and that M2-derived molecules such as TGF-beta might help drive type 2 immune responses. Because this report involved three people, it cannot show how common this mechanism is across IgG4-related disease overall. [19]

For patients and caregivers, these studies mainly add background about why IgG4-related disease can behave differently across people and over time, especially when scarring is part of the picture. They do not change diagnosis or treatment directly, but they support the idea that both immune activity and tissue scarring pathways may matter in the affected organ. What remains uncertain is how well these tissue gene signals predict symptoms or outcomes for an individual person, and whether targeting any single pathway would meaningfully change disease course.

This analysis used public gene expression datasets and machine learning to look for gene signals that move in the same direction in ANCA-associated kidney inflammation and IgG4-related disease. It identified two candidate markers, and one showed more consistent performance across internal and external checks, but the IgG4-related disease dataset was small and tissues differed between the diseases. [20]

ITGAM and CXCL1 were highlighted as cross-disease candidates based on expression patterns and model selection steps. ITGAM had stronger validation performance than CXCL1 when tested in an external ANCA dataset, while immune infiltration profiles differed, with neutrophil-dominant patterns in ANCA kidney disease and more plasma cells and M2 macrophage signals in IgG4-related disease datasets. [20]

For patients, this work is best viewed as early-stage research toward better biomarkers (measurable signals) rather than something ready for clinical use. The study suggests there may be some overlapping immune pathways between different inflammatory diseases, but it also highlights that the overall immune cell mix can be quite different. It remains uncertain whether these candidate markers would help with diagnosis, tracking, or understanding organ-specific symptoms in IgG4-related disease without larger, directly comparable patient samples.